Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efruxifermin - Akero Therapeutics

Next Previous
Drug Profile

Efruxifermin - Akero Therapeutics

Alternative Names: AKR-001; AMG-876; EFX; Fc-FGF21(RGE)

Latest Information Update: 20 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen
  • Developer Akero Therapeutics; Amgen
  • Class Anti-inflammatories; Antifibrotics; Antihyperglycaemics; Cardiovascular therapies; Fibroblast growth factors; Hepatoprotectants; Recombinant fusion proteins
  • Mechanism of Action Fibroblast growth factor 21 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
  • Phase II Liver cirrhosis
  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 07 Mar 2024 Akero Therapeutics plans a SYNCHRONY Outcomes phase III trial for Non-alcoholic-steatohepatitis in first half of 2024
  • 07 Mar 2024 Updated efficacy data from the phase IIb SYMMETRY trial in Non-alcoholic-steatohepatitis released by Akero Therapeutics
  • 04 Mar 2024 Updated efficacy and adverse event data from the phase IIb HARMONY trial in metabolic dysfunction-associated steatohepatitis (MASH) released by Akero Therapeutics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top